NKGen Biotech (NKGN) Stock Price, News & Analysis

Company Overview

NKGen Biotech, Inc. is a clinical-stage biotechnology company focused on developing natural killer (NK) cell therapies for cancer and neurodegenerative diseases. The company’s approach is designed to enhance the ability of NK cells to recognize and destroy abnormal cells without requiring genetic modification.

Its lead product candidate, SNK01, is an autologous NK cell therapy being evaluated in clinical studies involving cancer and Alzheimer’s disease. NKGen has also advanced SNK02, an allogeneic NK cell therapy intended for broader use across patients. The company’s development programs are aimed at solid tumors, hematologic malignancies and neurodegenerative conditions.

NKGen Biotech is based in the United States and is affiliated with South Korea-based NKMax Co., Ltd., which has conducted research into NK cell biology and related therapeutic technologies. The company’s U.S. operations are centered on clinical development and commercialization planning, while its programs have involved research and clinical activities spanning the United States and South Korea. Paul Song, M.D., serves as chief executive officer.

Key Stats

• Today's Range: $0.0111 to $0.0111
• 50-Day Range: $0.00 to $0.08
• 52-Week Range: $0.00 to $0.33
• Volume: N/A
• Average Volume: 6,347 shs
• Market Capitalization: $1.45 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 10/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:NKGN
• Previous Symbol: NYSE:NKGN
• CIK: 1845459
• Web: nkgenbiotech.com
• Phone: 949-396-6830
• Fax: N/A
• Employees: 26
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.68)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$82.94 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -479.36%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.02
• Quick Ratio: 0.02

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.68) per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 130,602,000
• Free Float: 40,291,000
• Market Cap: $1.45 million
• Optionable: Not Optionable
• Beta: 0.74